Sorrento Announces Positive Phase IIa Study Results of Abivertinib for the Treatment of Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL) and Its Plan for a Pivotal Phase III Study

Sorrento Therapeutics, Inc. has announced positive results from a phase IIa study of Abivertinib for the treatment of Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL) in China. Abivertinib is a novel Bruton's tyrosine kinase (BTK) inhibitor that targets BTK irreversibly. The study included 27 R/R MZL patients treated with Abivertinib, and the overall response rate (ORR) was 59.3%, with 3 pat..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 7. 6.
  • textsms

Catalent Finally Reports Earnings: Despite Losses, Revenue Beat Projections

Catalent, a healthcare product technology provider, has finally released its Q3 financial report for fiscal 2023 after delays in May. The company's revenue of $1.04 billion beat Wall Street projections despite being 19% below last year's Q3 revenue. However, the company reported an adjusted net loss of $17 million due to operational challenges and unexpected cost increases at some manufacturing ..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 14.
  • textsms